SETD2 and cancer: The TCGA data show a differential expression trend that underscores the complexity and tumor-dependent nature of SETD2 dysregulation in cancer pathogenesis, highlighting the need for further research to elucidate its precise mechanisms and therapeutic implications across diverse tumor types [7,12,13].